Drug firm Jubilant Life Sciences has received new drug application approval from the US health regulator for Drax Exametazime.

Jubilant Pharma Ltd, a wholly-owned subsidiary of the company, through its Canada-based arm Jubilant Draximage Inc has received new drug application (NDA) approval from the United States Food and Drug Administration (USFDA) for Drax Exametazime, Jubilant Life Sciences said.

"This approved NDA is indicated for leukocyte (white blood cell) labelled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease," it said in a BSE filing.


This is the sixth approval the company has received from the USFDA during the current financial year, it added. – Economic Times



Digital version